Smart nanoparticles for drug delivery: Boundaries and opportunities

Lee, Byung Kook; Yun, Yeon Hee; Park, Kinam

doi:10.1016/j.ces.2014.06.042

Cited by 146 publications

(90 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several hydrophobic drugs have been salvaged via the nanocrystal formulation method. The drugs were successfully developed, and approved by the FDA to treat a variety of indications ranging from dental disorders to cancer in the clinic . Depending on the disease, the approved formulations can be administered via different routes including oral, dermal, and parenteral.…”

Section: Introductionmentioning

confidence: 99%

“…The drugs were successfully developed, and approved by the FDA to treat a variety of indications ranging from dental disorders to cancer in the clinic. 14,[18][19][20][21][22][23][24][25][26][27][28] Depending on the disease, the approved formulations can be administered via different routes including oral, dermal, and parenteral. This highlights the versatility of a nanocrystal drug platform.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanocrystals: A perspective on translational research and clinical studies

Jarvis

Krishnan

Mitragotri

2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

Poorly soluble small molecules typically pose translational hurdles owing to their low solubility, low bioavailability, and formulation challenges. Nanocrystallization is a versatile method for salvaging poorly soluble drugs with the added benefit of a carrier‐free delivery system. In this review, we provide a comprehensive analysis of nanocrystals with emphasis on their clinical translation. Additionally, the review sheds light on clinically approved nanocrystal drug products as well as those in development.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nanocrystals: A perspective on translational research and clinical studies

Jarvis

Krishnan

Mitragotri

2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…The movement of the drug carrying nanoparticles in the tissue is caused by diffusion and convection mechanisms but diffusion is expected to be dominant in most cases [16]- [19]. At the tumor site, the drug carrier releases drug molecules of type X, which also diffuse in the tissue [18]. Hence, we can adopt Brownian motion to model the diffusion of Tx and X molecules with diffusion coefficients D Tx , and D X , respectively [7].…”

Section: A System Modelmentioning

confidence: 99%

“…2) Received Signal for Drug Delivery System: In drug delivery, the absorption rate ultimately determines the therapeutic impact of the drug [18], [20]. Thus, we formally define the absorption rate as the desired received signal, and make achieving a desired absorption rate the objective for system design.…”

Section: ) Time-variant Cirmentioning

confidence: 99%

Diffusive Mobile MC With Absorbing Receivers: Stochastic Analysis and Applications

Cao

Ahmadzadeh

Jamali

et al. 2019

IEEE Trans. Mol. Biol. Multi-Scale Commun.

View full text Add to dashboard Cite

This paper presents a stochastic analysis of the time-variant channel impulse response (CIR) of a three dimensional diffusive mobile molecular communication (MC) system where the transmitter, the absorbing receiver, and the molecules can freely diffuse. In our analysis, we derive the mean, variance, probability density function (PDF), and cumulative distribution function (CDF) of the CIR. We also derive the PDF and CDF of the probability p that a released molecule is absorbed at the receiver during a given time period.The obtained analytical results are employed for the design of drug delivery and MC systems with imperfect channel state information. For the first application, we exploit the mean and variance of the CIR to optimize a controlled-release drug delivery system employing a mobile drug carrier. We evaluate the performance of the proposed release design based on the PDF and CDF of the CIR. We demonstrate significant savings in the amount of released drugs compared to a constant-release scheme and reveal the necessity of accounting for the drug-carrier's mobility to ensure reliable drug delivery. For the second application, we exploit the PDF of the distance between the mobile transceivers and the CDF of p to optimize three design parameters of an MC system employing on-off keying modulation and threshold detection. Specifically, we optimize the detection threshold at the receiver, the release profile at the transmitter, and the time duration of a bit frame. We show that the proposed optimal designs can significantly improve the system performance in terms of the bit error rate and the efficiency of molecule usage.

show abstract

“…The last decade of the 2G period (i.e., 2000~2010)has focused on tumor-targeted drug delivery using nanoparticles. The seemingly promising nanoparticle approaches based on small animal models have not been successful in numerous clinical trials[9, 10]. The limited successes of the 2G technologies need careful analysis to make the current 3G technologies prepared for eventual clinical applications.…”

Section: History Of Drug Delivery Technologiesmentioning

confidence: 99%

Controlled Drug Delivery: Historical perspective for the next generation

Yun

Lee

Park

2015

Journal of Controlled Release

Self Cite

288

155

View full text Add to dashboard Cite

The modern day drug delivery technology is only 60 years old. During this period numerous drug delivery systems have been developed. The first generation (1950–1980) has been very productive in developing many oral and transdermal controlled release formulations for clinical applications. On the other hand, the second generation (1980–2010) has not been as successful in generating clinical products. This is in large part due to the nature of the problems to overcome. The first generation of drug delivery technologies dealt with physicochemical problems, while the second struggled with biological barriers. Controlled drug delivery systems can be made with controllable physicochemical properties, but they cannot overcome the biological barriers. The third generation (from 2010) drug delivery systems need to overcome both physicochemical and biological barriers. The physicochemical problems stem from poor water solubility of drugs, large molecular weight of peptide and protein drugs, and difficulty of controlling drug release kinetics. The biological barriers to overcome include distribution of drug delivery systems by the body rather than by formulation properties, limiting delivery to a specific target in the body. In addition, the body's reaction to formulations limits their functions in vivo. The prosperous future of drug delivery systems depends on whether new delivery systems can overcome limits set by human physiology, and the development process can be accelerated with new ways of thinking.

show abstract

Smart nanoparticles for drug delivery: Boundaries and opportunities

Cited by 146 publications

References 43 publications

Nanocrystals: A perspective on translational research and clinical studies

Nanocrystals: A perspective on translational research and clinical studies

Diffusive Mobile MC With Absorbing Receivers: Stochastic Analysis and Applications

Controlled Drug Delivery: Historical perspective for the next generation

Contact Info

Product

Resources

About